Dual antiplatelet therapy guided by platelet function testing

The Lancet

Volumn 390, Issue 10104, 2017, Pages 1718-1720

  Angiolillo, Dominick J ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; PRASUGREL; TICAGRELOR; ANTITHROMBOCYTIC AGENT;

ACUTE CORONARY SYNDROME; BLEEDING; BLOOD CLOTTING PARAMETERS; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DUAL ANTIPLATELET THERAPY; HUMAN; MAINTENANCE THERAPY; NOTE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; SOCIOECONOMICS;

ACUTE CORONARY SYNDROME; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS;

EID: 85028319490     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)32279-1     Document Type: Note

References (12)

1. Franchi, F, Angiolillo, DJ, Novel antiplatelet agents in acute coronary syndrome. Nat Rev Cardiol 12 (2015), 30–47.
2. Tantry, US, Bonello, L, Aradi, D, et al. Consensus and update on the definition of on treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J Am Coll Cardiol 62 (2013), 2261–2273.
3. Franchi, F, Rollini, F, Cho, JR, Ferrante, E, Angiolillo, DJ, Platelet function testing in contemporary clinical and interventional practice. Curr Treat Options Cardiovasc Med, 16, 2014, 300.
4. Price, MJ, Berger, PB, Teirstein, PS, et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305 (2011), 1097–1105.
5. Trenk, D, Stone, GW, Gawaz, M, et al. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (testing platelet reactivity in patients undergoing elective stent placement on clopidogrel to guide alternative therapy with prasugrel) study. J Am Coll Cardiol 59 (2012), 2159–2164.
6. Collet, JP, Cuisset, T, Range, G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med 367 (2012), 2100–2109.
7. Cayla, G, Cuisset, T, Silvain, J, et al. Platelet function monitoring to adjust antiplatelet therapy in elderly patients stented for an acute coronary syndrome (ANTARCTIC): an open label, blinded-endpoint, randomised controlled superiority trial. Lancet 388 (2016), 2015–2022.
8. Sibbing, D, Aradi, D, Jacobshagen, C, et al., on behalf of the TROPICAL-ACS Investigators. Guided De-Escalation of Antiplatelet Treatment in Acute Coronary Syndrome Patients Undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial. Lancet, 2017 published online Aug 27. http://dx.doi.org/10.1016/S0140-6736(17)32155-4.
9. Cuisset, T, Deharo, P, Quilici, J, et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J, 2017 published online May 16. DOI:10.1093/eurheartj/ehx175.
10. De Luca, L, D'Ascenzo, F, Musumeci, G, et al. Incidence and outcome of switching of oral platelet p2y12 receptor inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention: the SCOPE registry. EuroIntervention 13 (2017), 459–466.
11. Rollini, F, Franchi, F, Angiolillo, DJ, Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat Rev Cardiol 13 (2016), 11–27.
12. Moon, JY, Franchi, F, Rollini, F, et al. Role of genetic testing in patients undergoing percutaneous coronary intervention. Expert Rev Clin Pharmacol, 2017 published online July 10. DOI:10.1080/17512433.2017.1353909.